Fig. 1
From: Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
Changes from baseline at week 16 in a) PVRI, b) mPAP, and c) CI in DS versus non-DS patients. Treatment comparisons for pulmonary vascular resistance and cardiac index are in the form of ratios as the analyses were conducted on log transformed data. A log transformation of the week-16 data was used to achieve a normal distribution of the data. Log baseline value was included as a covariate in the analysis. DS = Down syndrome; PBO = placebo; CI = cardiac index; mPAP = mean pulmonary artery pressure; PVRI = pulmonary vascular resistance index; SIL = sildenafil